A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

520

Participants

Timeline

Start Date

February 15, 2024

Primary Completion Date

June 15, 2026

Study Completion Date

June 15, 2026

Conditions

Ovarian Cancer

Interventions

DRUG

SHR-1921

DRUG

carboplatin

carboplatin AUC 4

DRUG

carboplatin

carboplatin AUC 5

DRUG

platinum-based doublet chemotherapy

All Listed Sponsors

lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY

NCT06211023 - A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer | Biotech Hunter | Biotech Hunter